Renflexis is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Merck Sharp & Dohme Corp.. The primary component is Infliximab.
Product ID | 0006-4305_00f1b1ba-f1a8-4861-b6bb-d25d842cae6e |
NDC | 0006-4305 |
Product Type | Human Prescription Drug |
Proprietary Name | Renflexis |
Generic Name | Infliximab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-07-01 |
Marketing Category | BLA / BLA |
Application Number | BLA761054 |
Labeler Name | Merck Sharp & Dohme Corp. |
Substance Name | INFLIXIMAB |
Active Ingredient Strength | 100 mg/1 |
Pharm Classes | Tumor Necrosis |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2017-07-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761054 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-07-01 |
Marketing Category | BLA |
Application Number | BLA761054 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-07-01 |
Ingredient | Strength |
---|---|
INFLIXIMAB | 100 mg/1 |
SPL SET ID: | 3827e1be-f328-45f7-b113-311b57039f8c |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0006-4305 | Renflexis | infliximab |
78206-162 | Renflexis | infliximab |
57894-160 | INFLIXIMAB | INFLIXIMAB |
57894-030 | REMICADE | INFLIXIMAB |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RENFLEXIS 87480588 5542207 Live/Registered |
Merck Sharp & Dohme Corp. 2017-06-08 |
RENFLEXIS 86307793 5311653 Live/Registered |
Merck Sharp & Dohme Corp. 2014-06-12 |